Related by context. All words. (Click for frequent words.) 82 Incontinence Impact Questionnaire 62 Montgomery Åsberg Depression 60 Rating Scale MADRS 59 APACHE II 59 point Likert scale 59 Pain Rating Scale 58 QIDS SR 58 Acute Physiology 57 retrospective cohort 56 HRQL 56 State Exam MMSE 56 interrater reliability 56 Brief Psychiatric 56 BMI z 56 Rating Scale BPRS 56 multiple logistic regression 56 subscale scores 56 State Examination MMSE 56 CHADS 56 Univariate 56 subscales 55 DAS# CRP 55 subscore 55 logistic regression analyzes 55 % CI #.#-#.# [003] 55 Thrombolysis 55 PANSS 55 YMRS 55 IBDQ 55 EQ 5D 55 bivariate analyzes 54 biopsy Gleason 54 semiquantitative 54 HDRS 54 multivariate analyzes 54 IIEF 54 Primary endpoints 54 Histologic 54 Main Outcome Measure 54 logistic regression analysis 54 preoperatively 54 HADS 53 preoperative PSA 53 â ‰ ¥ 53 undetectable HBV DNA 53 PSQI 53 Global Impression CGI 53 subscores 53 ANCOVA 53 multicenter randomized controlled 53 SSRI SNRI 53 quetiapine risperidone 53 Abnormal Involuntary Movement 53 Visual Analog Scale 53 multivariate Cox 53 Visual Analog 53 femoral neck BMD 53 Stroke Scale NIHSS 53 randomized controlled trials RCTs 53 Likert 53 syndromal 53 MATERIALS AND METHODS 53 posttreatment 53 meta regression 53 #q# deletion syndrome 53 Status Scale EDSS 53 Postoperative 53 retest reliability 53 histopathologic 53 NSABP B 53 Pearson correlation coefficient 52 IPSS 52 NIH CPSI 52 underwent CABG 52 F FDG PET 52 Cochrane Database Syst Rev 52 univariate analyzes 52 nonobese patients 52 logistic regression model 52 nulliparous women 52 Echocardiographic 52 retrospective cohort study 52 HRQoL 52 Preoperatively 52 Radiographic 52 THIS STUDY 52 Multicenter 52 Treatment Outcome 52 logistic regression 52 underwent radical prostatectomy 52 transvaginal sonography 52 genotypic resistance 52 Depressive Symptoms 52 PANSS total 52 Arch Intern Med 52 Index CDAI 52 REYATAZ r arm 52 radical prostatectomy RP 52 Y BOCS 52 ug dose 52 univariate 52 Glasgow Coma Scale 52 GERD symptom 52 HAMD 52 Initiated Phase 52 Intervention Trial 52 postintervention 52 Regression analyzes 52 Pain Intensity 52 pT2 52 Scale PANSS 51 multivariate logistic regression 51 binary logistic regression 51 METHODS 51 Arch Neurol 51 % CI #.#-#.# [007] 51 Main Outcome Measures 51 chest radiographs 51 SF #v# 51 HRQOL 51 univariate analysis 51 Kaplan Meier analysis 51 MMSE score 51 NIHSS 51 Operative mortality 51 CD# [004] 51 NHANES III 51 P = .# 51 odds ratios ORs 51 #:#-# [033] 51 elevated ALT 51 Visual Analogue Scale VAS 51 postmenopausal osteoporotic women 51 Pathologic 51 Severity Index 51 J Clin Oncol 51 MMSE scores 51 myocardial viability 51 p = .# [002] 51 Nesiritide 51 Transesophageal 51 anthropometric measurements 51 bivariate 51 biochemical relapse 51 CCyR 51 Outcomes Study 51 psychiatric morbidity 51 posttest 51 Health Assessment Questionnaire 50 anthropometric measures 50 Generalized Anxiety Disorder 50 observational cohort study 50 longitudinal cohort study 50 Disease Activity 50 adjunctive placebo 50 CR nPR 50 UKPDS 50 Wechsler Adult 50 QoL 50 Histological 50 sonographic examinations 50 Infarct 50 ADAS cog 50 confidence intervals CIs 50 male Wistar rats 50 Montgomery Asberg Depression 50 ANOVA 50 Diseases Ninth 50 mcg QD 50 sd = 50 multivariable adjusted 50 BENCHMRK 50 angiographically 50 Histopathological 50 Treatment Diabetic Retinopathy 50 UPDRS motor 50 affective disorders 50 ADAS Cog 50 clinicopathologic 50 lateral radiographs 50 Angiographic 50 Coronary Artery Calcium 50 FDG PET imaging 50 RCTs 50 undergone radical prostatectomy 50 Kruskal Wallis test 50 underwent resection 50 NYHA functional class 50 MBq 50 DAS# [002] 50 calcaneal fractures 50 Likert scale 50 generalized estimating 50 RECIST Response Evaluation Criteria 50 Apgar scores 50 underwent liver transplantation 50 premorbid 50 VFQ 50 overnight polysomnography 50 J Natl Cancer Inst 50 multicentre randomized 50 symptom severity 50 prospective nonrandomized 50 pharmacokinetics PK 50 Epworth Sleepiness Scale 50 Interrater reliability 50 Subjective 50 histologically confirmed 50 variance ANOVA 50 exploratory endpoints 50 STAI 50 achieved CCyR 50 β blockers 50 clinico pathological 50 nontraumatic 50 BMI ≥ 50 UPDRS 50 prospective longitudinal 50 #:#-# [031] 50 IKDC 50 Prognostic Value 50 Randomized controlled 50 CR CRu 50 Liver biopsies 50 longitudinal observational study 50 psychiatric comorbidities 50 dimensional sonography 50 HAM D# 49 transthoracic echocardiography 49 Scale Cognitive Subscale 49 HOMA IR 49 T1a 49 Mini Mental 49 retrospectively reviewed 49 Neuropsychiatric Inventory 49 subtests 49 histologically proven 49 % CI #.#-#.# [008] 49 Crohn Disease Activity 49 Functional Capacity 49 multicentre prospective 49 preintervention 49 underwent surgical resection 49 FDG-PET/CT 49 covariate 49 MSCT 49 Placebo Controlled Study 49 psychometric properties 49 Carotid Endarterectomy 49 Stent Restenosis 49 Nat Genet 49 Cytogenetic 49 IQR 49 retrospectively analyzed 49 #:#-# [029] 49 suffered perforated bowels 49 Female Sexual Function 49 pT3 49 ECOG PS 49 prospective observational 49 prostate cancer CaP 49 BPS IC 49 extrapyramidal symptoms 49 TAXUS ARRIVE 49 BPRS 49 IRLS score 49 MDRD 49 lopinavir r arm 49 sociodemographic characteristics 49 MMSE 49 Randomized Controlled Trials 49 seropositivity 49 International Prostate Symptom 49 % Confidence Interval 49 #,#,#,#,#,# [003] 49 logistic regression models 49 Methods Retrospective 49 intima media thickness 49 polyarticular 49 Wilcoxon rank sum 49 MSLT 49 FACIT 49 visceral metastases 49 CARDIA 49 Common Toxicity Criteria 49 Stroke Scale 49 RENAL 49 % CI #.#-#.# [004] 49 NNT = 49 hours postdose 49 MADRS score 49 Coronary calcium 49 digital subtraction angiography 49 multivariable Cox 49 ACR Pedi 49 biochemical recurrence 49 Bonferroni 49 Secondary efficacy endpoints 49 depressive symptom 49 aged ≥ 49 semistructured interview 49 SDQ 49 nonobese 49 Cronbach alpha 49 Am J Cardiol 49 Meta analyzes 49 Structured Clinical 49 RECORD1 49 NMIBC 49 Flu Cy 49 BPH symptom 49 Prostate Cancer Prevention 49 Negative Syndrome 49 Comorbidities 49 BI RADS 49 SEER registries 49 microalbumin 49 Cognitive Function 49 Raloxifene Evaluation MORE 49 Ann Intern Med 49 pairwise comparisons 49 flutamide 48 ipsilateral stroke 48 mg administered orally 48 correlation coefficients 48 adenotonsillectomy 48 randomized multicenter trial 48 lipid lowering agents 48 PANSS scores 48 fatigue asthenia 48 -#.# ± [002] 48 somatization disorder 48 abnormal cytology 48 VLBW 48 ß blockers 48 Complication rates 48 trials RCTs 48 EURIDIS 48 male Sprague Dawley 48 PEPI 48 J Pediatr 48 postoperatively 48 HBeAg negative patients 48 LUTS 48 actigraphy 48 serum leptin 48 SGRQ 48 CHADS2 48 confirmed CCyR 48 suicide attempters 48 methacholine challenge 48 Child Behavior Checklist 48 mcg linaclotide 48 ADHD RS 48 Subtypes 48 parous women 48 Pharmacodynamic 48 retrospective observational study 48 nonmetastatic 48 WOMAC 48 PERMP 48 Outcome Measures 48 postprocedure 48 Bonferroni correction 48 Free Full Text 48 baseline PASI 48 RE LY ® 48 CAMMS# 48 laboratory abnormalities 48 unpaired t 48 DAS# scores 48 nonpsychotic 48 Functioning GAF 48 Sociodemographic 48 C#BL/#J mice 48 Subgroup analysis 48 amoxicillin clavulanate 48 ‰ ¥ 48 suppl. 48 LRTI 48 erection hardness 48 stepwise logistic regression 48 transthoracic 48 prucalopride 48 Arthritis Rheum 48 mg TID 48 Multiple logistic regression 48 divalproex sodium 48 FDG PET scans 48 antiretroviral naïve 48 chest radiography 48 SGAs 48 affective psychosis 48 PHQ 9 48 DAS# remission 48 CDAI 48 desvenlafaxine succinate 48 posttransplant 48 ALT elevation 48 undergoing peritoneal dialysis 48 Charlson Comorbidity Index 48 uteruses authorities 48 Pooled Analysis 48 RLAI 48 Stenting Trial 48 prospectively defined 48 ≥ 48 intact parathyroid hormone 48 Correlates 48 CNS LS 48 Stenting Trial CREST 48 Liraglutide Effect 48 EORTC QLQ C# 48 Preoperative 48 BPH LUTS 48 specific antigen PSA 48 CIMZIA TM certolizumab pegol 48 ALT flares 48 prognostic variables 48 diabetes mellitus DM 48 ACR# ACR# 47 Suppl. 47 hip BMD 47 Framingham Offspring 47 Lumbar spine 47 Coronary Artery Bypass Surgery 47 Pearson correlation coefficients 47 DEXA scans 47 Geriatric Depression 47 Univariate analysis 47 rFSH 47 relapsed MM 47 HGPIN 47 Decompensated Heart Failure 47 mm Hg diastolic 47 Wistar rats 47 perioperatively 47 QRS duration 47 LV ejection fraction 47 generalized edema 47 histologic findings 47 J Nutr 47 HYVET 47 ILLUSTRATE 47 Rating Scale UPDRS 47 prospectively enrolled 47 prospective randomized multicenter 47 lymphocytosis 47 postinjury 47 histopathological 47 oral diclofenac 47 intraclass correlation coefficients 47 bone scintigraphy 47 preoperative 47 spirometric 47 COR Analyzer 47 Multicenter AIDS 47 Fibromyalgia Impact Questionnaire 47 cerebrovascular accidents 47 prospectively randomized 47 Digital Mammographic Imaging 47 Solid Tumors RECIST 47 Double Blind Randomized 47 MetS 47 Physical Component 47 deoxy 47 Depressive symptoms 47 #Gy 47 colorectal adenoma 47 n = 47 azacytidine 47 PANSS Positive 47 CI -#.# 47 nonvertebral fractures 47 Erectile Function IIEF 47 Watchful Waiting 47 Likert scales 47 Partial Response 47 nausea photophobia 47 WOMAC pain 47 Randomised 47 TRUS 47 Comorbidity 47 dietary questionnaires 47 HSCT 47 Seattle Angina Questionnaire 47 EPDS 47 Neuropsychiatric Inventory NPI 47 Kaplan Meier curves 47 TRAS 47 nonparametric 47 evaluable subjects 47 immunohistochemical analysis 47 PREZISTA ritonavir 47 antiepileptics 47 Logistic regression analysis 47 haematologic 47 Psoriasis Area 47 thyroglobulin 47 Kruskal Wallis 47 tipranavir ritonavir 47 FASEB J. 47 CORE OM 47 recursive partitioning 47 serum estradiol 47 DSM IV Axis 47 Randomized Evaluation 47 psychiatric outpatients 47 Diagnostic Interview 47 interquartile range 47 NHANES surveys 47 Arm Shoulder 47 Antiviral Therapy 47 MADRS 47 convergent validity 47 amisulpride 47 efavirenz EFV 47 mg/m2 dose 47 PRECiSE 47 cTnI 47 microgram kg 47 liver biopsies 47 dosing cohorts 47 DLTs 47 tonsillar hypertrophy 47 ± SD 47 perforated bowels cervixes 47 Cystatin C 47 tertiles 47 prospective cohort 47 confidence interval CI 47 CFQ R 47 Secondary endpoints 47 Genotypes 47 KCCQ 47 Score DAS# 47 randomized crossover 47 EBMT criteria 47 semistructured interviews 47 oncologic outcomes 47 p ≤ 46 J Am Soc 46 hematological parameters 46 Multivariate analysis 46 Oral Fingolimod 46 Doppler sonography 46 DSM IV SCID 46 PLCO 46 emotional lability 46 pCR 46 Coronary CTA 46 mg q#h 46 Suppl 46 #OHD 46 Serum concentrations 46 nomogram 46 Symptom severity 46 Prognostic Significance 46 colonoscopy flexible sigmoidoscopy 46 sociodemographic factors 46 placebo PBO 46 polysomnographic 46 virological response 46 radical retropubic prostatectomy 46 mRS 46 #mg BID [001] 46 fluoxetine paroxetine 46 ECOG 46 adjunctive ABILIFY 46 melphalan prednisone 46 fraternal twin pairs 46 STEP BD 46 radical cystectomy 46 Severity Index PASI 46 nephron sparing surgery 46 periprocedural 46 remission CR 46 prospective multicenter study 46 tipranavir r 46 APOE genotype 46 clinically meaningful improvement 46 rs# [001] 46 interrater 46 T1DM 46 Charlson comorbidity index 46 umol L 46 mg QD 46 Scale EDSS score 46 headache abdominal pain 46 Eur Respir J 46 lopinavir r 46 blinded randomized placebo controlled 46 stage IIIB 46 digital rectal examination 46 ETDRS 46 Clinical Antipsychotic Trials 46 BI RADS ® 46 Kaplan Meier method 46 Fontan procedure 46 receiving ISENTRESS 46 sociodemographic variables 46 antidiabetic medication 46 differentially expressed genes 46 immunostaining 46 4mg/kg 46 Research Diagnostic Criteria 46 NIHSS score 46 Relapsing Remitting Multiple Sclerosis 46 detectable HCV RNA 46 regression analyzes 46 CRp 46 Mammographic 46 Cognitive Impairment 46 salivary cortisol 46 Partial Onset Seizures 46 #mg QD [001] 46 Study ARIC 46 Functional Outcomes 46 endoscopic remission 46 chi squared 46 headache nasopharyngitis 46 achieved sustained virological 46 Edinburgh Postnatal Depression 46 Sprague Dawley rats 46 endometrial thickness 46 #:#-# [037] 46 guanfacine extended release 46 psychiatric inpatients 46 Negative Symptoms 46 mg kg dose 46 subtest 46 ABC/3TC 46 somatoform disorders 46 cervical cytology 46 Endothelial Function 46 covariates 46 FFQ 46 Diagnostic Criteria 46 ug kg 46 J Foot Ankle 46 NHAMCS 46 ACC AHA 46 HbA 1c levels 45 CD4 CD8 45 Ejection Fraction 45 thrombus aspiration 45 KOOS 45 Sustained Efficacy 45 Headache Disorders 45 IFN alfa 45 #-#,# [007] 45 clinicopathological 45 RECIST criteria 45 Kidney Int 45 lymphopenia 45 intraclass correlation coefficient 45 TAXUS V 45 nasal symptom 45 allele frequencies 45 regression coefficients 45 CHD mortality 45 HIV seronegative 45 zonisamide SR 45 Long Term Outcomes 45 Suicidal Ideation 45 Skin sterol 45 Baseline characteristics 45 fasting lipid 45 nonrandomized 45 elevated transaminases 45 linear regressions 45 fasting plasma 45 insulin detemir 45 Baltimore Longitudinal Study 45 Coronary artery calcium 45 CORD II 45 Mental Component 45 Br J Cancer 45 NPRS 45 Common Terminology Criteria 45 risperidone olanzapine 45 substudy 45 neurocognitive function 45 cells uL 45 Desvenlafaxine Succinate 45 GH deficiency 45 TEAEs 45 J Virol 45 bepotastine besilate nasal spray 45 mild renal insufficiency 45 advanced neoplasia 45 EuroSCORE 45 Score DAS 45 MVax R 45 treatment naive genotype 45 ng dl 45 Endarterectomy 45 CAPRA 45 HAM D 45 Prospective Multicenter 45 Treated Patients 45 Supplementary Appendix 45 primary percutaneous coronary 45 eNO 45 FDA defined valvulopathy 45 Dyspnea 45 NAMCS 45 concomitant medications 45 fructosamine 45 pain catastrophizing 45 enthesitis 45 dyspnoea 45 seroconverted 45 Suboptimal 45 non hematologic toxicities 45 aspartate aminotransferase AST 45 certolizumab 45 beta blocker therapy 45 #mg QD [002] 45 preoperative intraoperative 45 Descriptive statistics 45 drug eluting stent implantation 45 hsCRP levels 45 HBeAg positive 45 superficial edema 45 Longitudinal 45 timepoints 45 ALLHAT 45 bronchoalveolar lavage fluid 45 Subgroup analyzes 45 Diabetic Foot Ulcer 45 = #.#-#.# 45 ULORIC 45 Screening Trial DMIST 45 microalbumin test 45 FOLPI 45 rizatriptan 45 CI #.#-#.# [001] 45 Ann Emerg Med 45 null responder HCV 45 Mantel Haenszel 45 Sustained Virologic Response 45 Mol Psychiatry 45 cerebral infarctions 45 ST Segment Elevation 45 5 hydroxytryptamine 45 baseline HbA1c 45 metaanalysis 45 serum cortisol 45 AST ALT 45 elevated LDH 45 conducted retrospective cohort 45 prospective observational cohort 45 variant rs# 45 mg clopidogrel 45 Patients Receiving 45 de novo AML 45 TNM staging 45 Women Ischemia Syndrome 45 Arch Facial Plast 45 nonrandomized studies 45 achieved ACR# 45 linear regression models 45 Supplementary Table 45 Cardiotoxicity 45 Evaluable 45 Negative Symptom Scale 45 Distress Scale 45 neuropathy sensory 45 J Clin Psychiatry 45 p = #.# [003] 45 undergoing coronary angiography 45 HCV Genotype 45 psychopathological symptoms 45 virologic responses 45 dichotomized 45 adverse reactions ≥ 45 AIR CF1 45 osteopenic 45 doxorubicin cyclophosphamide 45 mcg albinterferon alfa 2b 45 CAVEATS 45 Kellgren Lawrence 45 treatment naïve genotype 44 Lewy bodies DLB 44 Am J Epidemiol 44 PSA nadir 44 placebo controlled dose escalation 44 Postmenopausal Women 44 EDSS scores 44 Assessment Questionnaire 44 r2 = 44 fasting glucose 44 nonfasting 44 HIV uninfected 44 degenerative lumbar 44 TLUS 44 #mg/day [002] 44 SSRI citalopram 44 Solid Tumors 44 #,#,#,# [006] 44 sensory neuropathy 44 BCG vaccinated 44 neoadjuvant treatment 44 CI = 44 Appropriateness Criteria 44 Pharmacokinetic 44 ENGAGE AF TIMI 44 VcMP 44 prospective randomized controlled 44 Cognitive Abilities Test 44 liver transplant recipients 44 intracardiac 44 Oswestry Disability Index 44 Score IPSS 44 CGIC 44 Subsets 44 Abstract Number 44 Clinician Administered PTSD 44 F FDG 44 undetectable HCV RNA 44 Young Adults CARDIA 44 comorbid psychiatric disorders 44 aminotransferase levels 44 Eur Urol 44 HT 1A 44 #,#,#,# [011] 44 epigastric pain 44 seronegative 44 myocardial revascularization 44 nondiabetic subjects 44 = .# 44 Unified Parkinson Disease 44 GLIADEL R Wafer 44 Biol Psychiatry 44 ICD shocks 44 Key secondary endpoints 44 Somnolence 44 ONGLYZA saxagliptin 44 evaluable 44 NCT# ClinicalTrials.gov 44 Pharmacokinetics PK 44 PROactive study 44 muscle biopsies 44 TURBT 44 Percutaneous Coronary Interventions 44 extracapsular extension 44 Non Responders 44 hip resurfacing arthroplasty 44 hypocalcemia 44 TIMP 44 Acid Digestion 44 DLQI 44 % CI #.#-#.# [005] 44 creatinine ratio 44 Sentinel Lymph Node 44 potential confounders 44 Intracerebral 44 PON1 activity 44 mean ± SEM 44 comorbid conditions 44 HbA1c levels 44 electroencephalograms EEG 44 Screening Trial 44 adiponectin concentrations 44 HAQ DI 44 metabolite concentrations 44 baseline serum creatinine 44 Obes Res 44 PCWP 44 docetaxel prednisone 44 Neuropsychological Status 44 clinicopathological features 44 postvaccination 44 APGAR 44 Lower Limb 44 BENICAR HCT 44 hypogonadal men 44 normotensive 44 CRQ 44 mITT population 44 glucose insulin 44 System IPSS 44 Coronary Revascularization 44 Questionnaire 44 uM 44 cytoreductive nephrectomy 44 somatic symptom 44 Immunomodulatory 44 #:#-# [002] 44 intratympanic 44 URTI 44 radical nephrectomy 44 Placebo controlled 44 Framingham Offspring Study 44 #mg/day [001] 44 anthropometric 44 highest tertile 44 e# [005] 44 Lesion 44 HealthGrades analyzed 44 dyads 44 categorical variables 44 interleukin IL 44 N Engl J 44 macroalbuminuria 44 CANCIDAS 44 squamous intraepithelial lesions 44 microg 44 Predictors 44 urinary sodium excretion 44 #,#,#,#,# [008] 44 Polyp Prevention Trial 44 Acute Coronary Syndromes ACS 44 psychosocial functioning 44 sUA 44 zolmitriptan 44 median PFS 44 dyssynchrony 44 Chronic Constipation 44 Excretion 44 Narcissistic Personality Inventory 44 multivariate regression analysis 44 GH deficient 44 Doppler ultrasonography 44 psychiatric diagnoses 44 Cancer Incidence Mortality 43 Exclusion criteria 43 fasting insulin 43 Cochrane Database Syst Rev. 43 Data Extraction 43 p = #.# [002] 43 Cardiovascular Risk Factors 43 secondary efficacy endpoints 43 syndromic 43 EDSS score 43 PMID # [002] 43 Nutrition Examination Surveys NHANES 43 transrectal ultrasound guided 43 plasma renin activity 43 sustained virological response 43 OSDI 43 troponin T 43 randomisation 43 -#.# log# copies mL 43 CLL SLL 43 Suicidal ideation 43 Logistic regression analyzes 43 Gravimetric finish 43 meta analysis 43 Likert Scale 43 conventional cytology 43 neuropsychological assessment 43 Psychiatry Res 43 leucopenia 43 Cancer Res 43 Supplemental Figure 43 Insulin sensitivity 43 maximal treadmill 43 pelvic ultrasound 43 Teriflunomide 43 endoscopic examinations 43 neuropsychological assessments 43 mg RDEA# 43 nonmetastatic prostate cancer 43 Prognostic Index 43 Standardized Assessment 43 Pediatric Patients 43 Elastography 43 #S #S [001] 43 SPECT MPI 43 doi #.# 43 doi #.#/S#-# 43 polysomnography PSG 43 oral hypoglycemic 43 Kaplan Meier estimates 43 deCODE AF TM 43 Pharmacodynamics 43 baseline LDH 43 methylprednisolone 43 Adjunctive 43 REVIVE Diabetes 43 prospective observational studies 43 #.#/#.# mm Hg [002] 43 CTEPH 43 OPCAB 43 Atherosclerosis Risk 43 Numeric Rating Scale 43 ziprasidone 43 patients evaluable 43 TMC# C# 43 AVERROES 43 mu opioid agonist analgesics 43 vitreous floaters 43 Natalizumab 43 TIMP 1 43 Neonates 43 Prostate Lung Colorectal 43 NLSY